Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 14 · below the Ichimoku cloud · RSI 23 (oversold) · MACD below its signal · 2% above its 52-week low
None of the 29 investors followed here reported a position in DRMA in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a DRMA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 13, 2026 | Proehl Gerald TChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 170.1K | — |
| Aug 13, 2026 | Van Hoose Kyri KChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 102K | — |
| Jun 15, 2026 | Scott Kathleen DDirector | Sale at price 1.19 per share. | 11 | $13 |
| Feb 16, 2026 | Bedoya-Toro Munera Maria EOfficer | Purchase at price 1.27 per share. | 1K | $1.27K |
| Dec 22, 2025 | Proehl Gerald TChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 612.7K | — |
| Dec 22, 2025 | Van Hoose Kyri KChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 122.5K | — |
| Jan 22, 2025 | Hale David FDirector | Stock Award(Grant) at price 0.00 per share. | 78.7K | — |
| Jan 20, 2025 | Fisher MaryDirector | Stock Award(Grant) at price 0.00 per share. | 196.9K | — |
| Jan 20, 2025 | Van Hoose Kyri KChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 78.7K | — |
| Jan 20, 2025 | Proehl Gerald TChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 787.4K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.0 | -46.7 | 0.8 | 13.2 | -5.1 | -0.8 | -9.3 | 10.3 | -14.7 | -21.8 | −62.9% | ||
| 2025 | -8.9 | -7.3 | -5.3 | -22.4 | -14.1 | -18.7 | 6.5 | -7.9 | -12.5 | -31.9 | -8.2 | -26.1 | −82.8% |
| 2024 | -19.5 | -6.5 | -10.5 | -20.4 | -21.8 | -37.7 | -28.0 | 1.2 | -5.7 | -22.6 | -11.2 | 19.7 | −85.2% |
| 2023 | -33.0 | -5.1 | -69.0 | 27.1 | -2.4 | 3.1 | -21.2 | -4.6 | -14.5 | -44.6 | 26.9 | -18.1 | −90.7% |
| 2022 | 29.3 | -45.3 | 1.6 | -17.6 | -24.3 | -16.7 | -10.6 | -1.9 | -8.8 | 27.1 | -2.4 | -36.6 | −76.5% |
| 2021 | -22.6 | 4.0 | -41.8 | -36.0 | −70.0% |
Buy / hold / sell counts
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.